ARCA biopharma Inc. (NASDAQ: ABIO) is 17.15% higher on its value in year-to-date trading and has touched a low of $2.21 and a high of $22.00 in the current 52-week trading range. The ABIO stock was last observed hovering at around $6.69 in the recent trading session, with the current loss setting it -0.01% off its average median price target of $7.00 for the next 12 months. It is also 4.57% off the consensus price target high of $7.00 offered by 1 analysts, but current levels are 4.57% higher than the price target low of $7.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
At last check, trading at $6.68, the stock is -4.31% and 7.36% above its SMA20 and SMA50 respectively. However, with a current trading volume of 0.68 million and changing -0.18% at the moment leaves the stock 29.63% off its SMA200. ABIO registered -2.48% loss for a year compared to 6-month gain of 17.99%. The firm has a 50-day simple moving average (SMA 50) of $7.37 and a 200-day simple moving average (SMA200) of $5.08.
The stock witnessed a -19.40% loss in the last 1 month and extending the period to 3 months gives it a 142.39%, and is 1.06% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.55% over the week and 9.35% over the month.
Distance from 52-week low is 202.17% and -69.65% from its 52-week high.
ARCA biopharma Inc. (ABIO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for ARCA biopharma Inc. (ABIO) is a “Buy”. 1 analysts offering their recommendations for the stock, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
ARCA biopharma Inc. is expected to release its quarterly report on 08/05/2020 and quarterly earnings per share for the current quarter are estimated at $0.The EPS is expected to grow by 59.80% this year.
ARCA biopharma Inc. (ABIO) Top Institutional Holders
18 institutions hold shares in ARCA biopharma Inc. (ABIO), with 9.07k shares held by insiders accounting for 0.57% while institutional investors hold 13.36% of the company’s shares. The shares outstanding are 1.59M, and float is at 1.18M with Short Float at 1.32%. Institutions hold 13.28% of the Float.
ARCA biopharma Inc. (ABIO) Insider Activity
A total of 0 insider transactions have happened at ARCA biopharma Inc. (ABIO) in the last six months, with sales accounting for 0 and purchases happening 0 times.